Before I dive into my first column, I figure I should introduce myself. I was born Mary Jean Dunsdon, youngest of four, to a Top Gun fighter pilot and a macramé hut/craft store owner. So I come by my current profession honestly. I have been unapologetic about my marijuana use and food production since 1993. I sold my first cookies on the world-famous, clothing-optional Wreck Beach that same year.
Before selling cookies, I sold slices of watermelon and T-Shirts to nude people. The T-Shirts had pictures of my best friend on them. He was an 80-year-old Irish bootlegger named Paddy White. Paddy loved to smoke pot. I sold the watermelon for $2 a slice—except to children. It was always free for children. This is where I got my name, Watermelon.
Since those early days, I have easily made and sold more than 1 million Ginger Extra Snap Cookies, Rum-Resin Balls, Bud-der Tarts, Weedish Meatballs, Spanakopita Puff Pastries, Nice Cream Cones, Quiche Your Ass Goodnights and so much more. I love to host marijuana-tasting salons in my home a few times each year. I cannot stress how important it is to know about serving size and cannabis conversion when hosting such parties. I want everybody to have a great time without sleeping over or freaking out. I have some great party tricks I will share with you in a later column, but for starters, I want to break down my rather simple process, step by step. When it comes to baking edibles, there are three steps to nail:
Making your shake flour
Determining your serving sizes
Converting your cannabis
These processes can be used for almost any recipe. I always encourage responsible edible creations that can be enjoyed by the average person. Advanced edible eaters can have two servings. For me, the easiest method of all for making edibles is by starting with some shake flour.
Making Shake Flour
Shake flour, quite simply, is finely ground, dried cannabis flowers and/or leaves. To make your own, pulverize cannabis flowers and/or leaves into a fine flour using a blender or coffee grinder, and then sift off any fibrous material. Store in an airtight container in the fridge until you’re ready to use it on a recipe-by-recipe basis.
Serving Sizes & Portion Control
The most important kitchen tool you will need for creating edibles is a scale. My serving guidelines, which I believe offer the perfect dose for the average person, is 0.5-0.75 grams per serving. So, if your recipe says serves 10, you will weigh up enough shake flower for 10 servings only. This equates to 5-7.5 grams, depending on the quality of your shake/bud. Don’t be a hero unless you like sleepovers. Less is always more. A little goes a long way. As my mama says, “You can always go back for seconds.”
You can then add your weighed shake to the fat, oil, alcohol or whatever you are using for your cannabis conversion. This helps avoids any confusion on how much to eat, or how much pre-made canna butter to add.
Cannabis Conversion
You need to convert dried cannabis to make it active, meaning it gets you high when you ingest it. Scientifically speaking, you need to knock the carbon molecule off the cannabis so it can bind to your cannabinoid receptors. Cannabis molecules cannot easily bind to your receptors with the carbon molecule intact. This is similar to a key that won’t fit into a lock. After you knock the carbon molecule off, the key fits perfectly.
You can knock carbon molecules off using heat, alcohols or fats. This is the process of cannabis conversion taking place. There are many different types of fats you can use to convert cannabis for edibles, including butter, coconut oil and bacon fat. There are also many different types of alcohol you can used to convert cannabis for edibles, including rum, vodka and black sambuca. Another way to covert cannabis is using dry-cooking techniques done in an oven or a slow cooker, and some patience.
Originally Posted at: Hydrolife
Former Super Bowl champion and Chicago Bears quarterback Jim McMahon credits
medical marijuana for helping him recover from the chronic pain he
developed from his long and arduous career as a football player in the
NFL.
Now 56, McMahon has been plagued by debilitating health problems
following his 15-year career in the National Football League which
included multiple concussions and a broken back. Since retiring from
football, McMahon has been diagnosed with early onset dementia and
experiences severe headaches, depression, memory loss, and vision and
speech problems. As a result of all these health issues, McMahon has
joined other players in a pending class-action lawsuit accusing the NFL
of negligence and misconduct in handling concussions.
Since he came forward with his health issues, McMahon said he has been
feeling significantly better after his recent chiropractic neck
treatments, but says medical marijuana got him off the copious amounts
of prescription narcotic painkillers that he took throughout his career.
McMahon admitted to taking nearly 100 Percocet pills a month for pain
in his shoulders, neck and arms before he received his medical
card. “They were doing more harm than good,” he said. “This medical
marijuana has been a godsend. It relieves me of the pain — or thinking
about it, anyway. More people should have access to this wonderful
plant.”
McMahon received his doctor’s recommendation for medical cannabis
in his home state of Arizona after it was approved by a voter referendum
in 2010. However, his focus lately has been on the state of Illinois,
where he is advocating for chronic pain to be added to the list of
acceptable conditions for medical marijuana patients.
via: Medical Jane
As medical marijuana becomes legal in
more states across the country, there’s been a spike in public interest
to see whether cannabis can effectively treat mood disorders such as
anxiety, depression, and psychosis that are commonly associated with
bipolar disorder. Unfortunately, there are conflicts in scientific
consensus for both supporting and opposing views of cannabis use for the
treatment of mood disorders. Some studies have linked marijuana use with early-onset psychosis, while others suggest there are anti-psychotic benefits of cannabis in bipolar disorder patients.
It has been shown that cannabidiol has anti-psychotic properties, particularly anxiolytic benefits in humans. CBD possesses hypnotic, anti-convulsive, neuroprotective, and anti-stress
benefits. Based on this evidence, research studies have begun to
investigate the anxiolytic and antipsychotic benefits of CBD, which may
be useful in effectively treating bipolar disorder.
The Neurochemistry of Bipolar Disorder and Cannabinoids
A dysfunctional endocannabinoid system (EC) has been implicated
in mood disorders such as bipolar disorder, and modulation of the EC
system by exogenous cannabinoids such as cannabidiol,
tetrahydrocannabinol and anandamide can potentially treat bipolar
disorder symptoms by exerting antipsychotic, anticonvulsant, and
anxiolytic effects. Research studies have demonstrated
the antipsychotic mechanism action of cannabidiol. Administration of
cannabidiol may indirectly influence endogenous anandamide signaling by
inhibiting intracellular metabolism by fatty acid amide hydrolase
(FAAH). Elevated levels of anandamide can attenuate mood disturbances
and treat bipolar disorder symptoms.
Research studies have pointed
out the role of the dopamine (DA) system in mood disorders, including
bipolar disorder. The key role of the mesoaccumbens DA system has been
proven in the reward pathway (neural circuitry) and motivational
behaviors. Experimental studies being conducted to investigate
the efficacy of anti-psychotic drugs are based on the hypothesis of
dopamine, glutamate, and other neurotransmitters. These drugs exhibit antagonism to dopamine D2 receptors which is commonly linked
with hyperprolactinemia due to action of anterior-pituitary
mammotrophic cells. These drugs are called typical anti-psychotics
(Clozapine) which cause Parkinson-like symptoms, while atypical
anti-psychotics are also effective without causing serious adverse events, which can be confirmed by a catalepsy test.
Atypical anti-psychotic drugs inhibit
hyperlocomotion and the stereotype that results due to dopamine
antagonists at lower doses. Effective anti-psychotic action requires the
blocking of D2 receptors as well as glutamatergic N-methyl-D-aspartate (NMDA) receptors.
A comparative study assessed
the anti-psychotic efficacy of haloperidol (an anti-psychotic drug) and
cannabidiol (CBD) found that CBD inhibited hyperlocomotion without
causing catalepsy, even at higher doses; while haloperidol caused
prolactin disturbances. The pharmacological action of CBD mimics
clozapine. Another neurochemical experimental study reported similar results. These results prove that CBD acts like an atypical anti-psychotic drug without causing serious and long-term side effects.
One study
investigated the anti-depressive action of CBD in an experimental
animal model (AKA olfactory bulbectomy mouse model) of depression (OBX).
The results suggest that cannabidiol exerted rapid and sustained
antidepressant action in the depressed animals by significantly
augmenting cortical serotonin and glutamate levels in a dose-dependent
manner. Receptor studies have shown that the action was exerted via a
5-HT1A
receptor-dependent mechanism, which represents novel drug
functionality. After prolonged CBD administration notable adaptive
changes were documented in pre and post-synaptic 5-HT1A receptor action.
CBD can inhibit glutamate toxicity and offers anti-convulsant and mood-stabilizing benefits, which are similar
to the benefits of conventional therapeutic drugs such as valproate and
lithium that are indicated for bipolar disorder. In open-label human
clinical trials, CBD has significantly reduced
psychotic symptoms and normalized motor functions in psychiatric
patients. These benefits can be useful to treat manic episodes in
bipolar disorder patients.
Cannabinoids influence mood
perceptions and exert anti-depressant action by acting as an agonist in
central CB1 receptors. 5-HT is believed to be responsible for mood
control and implicated in antidepressant-like actions. Research evidences
have pointed out the action of CBD in the serotonin (5-HT) system and
related neurons. Administration of CB1R agonists such as
phytocannabinoids into the ventromedial prefrontal cortex of the brain
has resulted in enhanced 5-HT neuronal activity and CB1R-dependent
antidepressant-like effects in the experimental animals. This study
clearly shows the dose-dependent antidepressant benefit of CBD, which
can be particularly useful for the treatment of mood disorders,
including bipolar disorder.
More Including: The Neuroprotective, Anti-psychotic, and Anxiolytic Benefits of CBD at Marijuana Times.